Ignite Creation Date:
2025-12-24 @ 5:47 PM
Ignite Modification Date:
2025-12-30 @ 5:12 AM
Study NCT ID:
NCT06930768
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-11-19
First Post:
2025-04-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014647', 'term': 'Varicose Ulcer'}], 'ancestors': [{'id': 'D014648', 'term': 'Varicose Veins'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D007871', 'term': 'Leg Ulcer'}, {'id': 'D012883', 'term': 'Skin Ulcer'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D059039', 'term': 'Standard of Care'}], 'ancestors': [{'id': 'D019984', 'term': 'Quality Indicators, Health Care'}, {'id': 'D011787', 'term': 'Quality of Health Care'}, {'id': 'D006298', 'term': 'Health Services Administration'}, {'id': 'D017530', 'term': 'Health Care Quality, Access, and Evaluation'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The subject will be randomized to one of the following treatments:\n\n* Standard of care\n* NeoThelium FT in addition to standard of care'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 132}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2025-12-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2026-10-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-18', 'studyFirstSubmitDate': '2025-04-01', 'studyFirstSubmitQcDate': '2025-04-08', 'lastUpdatePostDateStruct': {'date': '2025-11-19', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-04-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-08-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Wound closure rate in comparison to initial area', 'timeFrame': 'Day 0 through Day 84', 'description': 'Wound healing rate vs wound area categories 0.5-1 cm2, \\>1-3cm2, \\>3-5cm2, etc.'}, {'measure': 'Adverse Events and Serious Adverse Events', 'timeFrame': 'Day -14 through 91 days', 'description': 'The number and nature of adverse events (AEs) and series adverse events (SAEs) occurring during the study will be tracked and reported.'}], 'primaryOutcomes': [{'measure': 'Complete Wound Closure', 'timeFrame': '1-12 weeks', 'description': 'The primary endpoint will be the percentage of target ulcers that achieve complete wound closure.'}], 'secondaryOutcomes': [{'measure': 'Percentage Wound Area Change', 'timeFrame': '1-12 weeks', 'description': 'The percentage change in wound area from TV-1 to TV-13 will be measured weekly using digital photographic planimetry and physical examination.'}, {'measure': 'Time to Closure', 'timeFrame': '1-12 weeks', 'description': 'Average number of grafts and/or weeks used to achieve wound closure'}, {'measure': 'Follow-Up Closure', 'timeFrame': '2 weeks', 'description': 'Number of wounds remaining closed during the 2-week follow-up'}, {'measure': 'Pain Assessment', 'timeFrame': 'Day 0, Day 14, Day 35, Day 56, Day 84', 'description': 'Change in pain associated with the target ulcer will be assessed using the Numeric Pain Rating Scale at designated time points'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Chronic wounds', 'Wound Medicine', 'Cellular, Acellular, Matrix-like Product (CAMP)', 'Cellular and/or Tissue Product (CTP)', 'Dehydrated Complete Human Placental Membrane (dCHPM)'], 'conditions': ['Venous Leg Ulcer']}, 'descriptionModule': {'briefSummary': 'This is a randomized controlled trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating venous leg ulcers.', 'detailedDescription': 'This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet the study requirements during screening will be randomly assigned to one of two groups: either standard of care alone, or standard of care plus NeoThelium FT. As this is a post-marketing study, it will gather information about how effective the treatment is in treating venous leg ulcers. All subjects will complete two week screening phase prior to being randomized into a treatment arm. Treatment arms will consist of NeoThelium FT in conjunction with standard of care, vs. standard of care alone. The primary endpoint will be the percentage of target ulcers that achieve complete wound closure within 16 weeks. Secondary endpoints consist of wound area reduction rates, time to closure, follow-up closure, and pain assessment.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Male or Female, 18 years of age or older\n2. Subject has a medical diagnosis of Venous Insufficiency with an open wound to the lower extremity\n3. Subject has a Venous Leg Ulcer present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC\n4. Subject has a Venous Leg Ulcer with a historical wound measurement showing less than 50% healing in 30 days prior to randomization\n5. Subject has a Venous Leg Ulcer with screening wound measurement showing less than 25% healing in 14 days prior to randomization\n6. Subject has a Venous Leg Ulcer Wagner 1, 2, and 3 without infection or clinically visible exposed bone\n7. Index ulcer is a minimum of 1cm2 and a maximum of 40cm2 at first treatment visit\n8. Venous Leg Ulcer is being treated with compression therapy for 14 days prior to randomization\n9. Adequate circulation of ulcer demonstrated by an ABI of \\>0.7 and \\<1.3, or TBI of \\>0.6 within 30 days prior to randomization\n10. Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.\n11. Index ulcer is free of necrotic debris prior to NeoThelium FT application\n12. Female subjects of childbearing potential having a negative pregnancy test prior to randomization\n13. Subject is able and willing to follow the protocol requirements\n14. Subject had signed informed consent\n15. If 2 or more ulcers are present, the ulcers must be separated by at least 1 cm\n\nExclusion Criteria:\n\n1. Subject has a known life expectancy of \\<1 year\n2. Subject is unable to comply with protocol treatment\n3. Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing\n4. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound\n5. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator\n6. Known contraindications to tissue-engineered allograft\n7. Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing\n8. Wound reduces in area by ≥25% after 14 days of SOC prior to randomization\n9. Subject is pregnant or breastfeeding\n10. Subject with history of immunosuppressant treatment (systemic corticosteroids \\>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the ulcer surface for \\>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study\n11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization\n12. Venous Leg Ulcer with active infection\n13. Wound depth with visible exposed bone\n14. HBOT within 14 days prior to randomization\n15. Revascularization surgery on the index ulcer leg within 30 days of screening phase\n16. Index ulcer suspicious of neoplasm in the opinion of the principal investigator'}, 'identificationModule': {'nctId': 'NCT06930768', 'briefTitle': 'Evaluating the Efficacy of NeoThelium FT in the Treatment of Venous Leg Ulcers', 'organization': {'class': 'INDUSTRY', 'fullName': 'NuScience Medical Biologics, LLC'}, 'officialTitle': 'Evaluation of the Efficacy of NeoThelium FT in the Healing of Venous Leg Ulcers: A Randomized Controlled Multicenter Trial', 'orgStudyIdInfo': {'id': 'VELOCITY'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'No Intervention: Standard of Care', 'description': 'Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading', 'interventionNames': ['Other: Standard of Care']}, {'type': 'EXPERIMENTAL', 'label': 'Intervention: NeoThelium FT & Standard of Care', 'description': 'Wound cleansing, sharps debridement, NeoThelium FT application, Dressing for moisture balance, Offloading', 'interventionNames': ['Other: NeoThelium FT']}], 'interventions': [{'name': 'Standard of Care', 'type': 'OTHER', 'description': 'Wound cleansing, Sharps debridement, Dressing for moisture balance, Offloading', 'armGroupLabels': ['No Intervention: Standard of Care']}, {'name': 'NeoThelium FT', 'type': 'OTHER', 'description': 'NeoThelium FT is a dehydrated wound covering derived from donated human placental tissue. NeoThelium FT is a dual-layer membrane with amnion and chorion combination layers.', 'armGroupLabels': ['Intervention: NeoThelium FT & Standard of Care']}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Angelina Ferguson, DNP', 'role': 'CONTACT', 'email': 'info@sygnola.com', 'phone': '(985) 629-4013'}, {'name': 'Sarah Moore, MBE', 'role': 'CONTACT', 'email': 'info@sygnola.com', 'phone': '(985) 629-4013'}], 'overallOfficials': [{'name': 'Angelina Ferguson, DNP', 'role': 'STUDY_DIRECTOR', 'affiliation': 'SygNola, LLC'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'NuScience Medical Biologics, LLC', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'SygNola, LLC', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}